Sign in to follow
Search Results

0 results for 'CVS Health'

You can use to get even better search results
August 27, 2001 |

After the Jurors Go Home

After large jury verdicts grab the headlines, there is rarely any follow-up examining what actually happens to the awards once the juries go home. The National Law Journal has filled this void by returning to see what happened to 100 of the several hundred verdicts of $1 million or more rendered in 1997. Thirty-four of the verdicts are in this section, and the remaining 66 will be presented on Thursday.
32 minute read
March 09, 2011 |

News In Brief

4 minute read
September 10, 2010 |

2nd Circuit Declines En Banc Review of Drug 'Pay-to-Delay' Ruling

The 2nd Circuit has refused to reconsider en banc its holding that antitrust laws are not violated when drug patent holders pay manufacturers of generic alternatives to keep competing products off the market. The active members of the circuit issued a brief ruling Tuesday saying they had voted to deny rehearing en banc a case in which a three-judge panel in April affirmed summary judgment for Bayer AG on a Sherman Act challenge concerning a so-called "pay-for-delay" agreement involving the antibiotic drug Cipro.
5 minute read
In the Matters of Geraldine A., Respondents, D-16725/09
Publication Date: 2010-11-30
Practice Area: Juvenile Law
Industry:
Court: Family Court, Queens County
Judge: Judge John M. Hunt
Attorneys:
For plaintiff:
For defendant:
Case number: D-16725/09

Cite as: Matters of Geraldine A., D-16725/09, NYLJ 1202475438937, at *1 (Fam., QU, Decided November 23, 2010)Judge John M. HuntDecided: N

Law Journal Press | Digital Book Health Care Benefits Law Authors: Jeffrey D. Mamorsky View this Book

View more book results for the query "CVS Health"

May 24, 2004 |

VERDICTS & SETTLEMENTS

Summaries of verdicts and settlements as reported in The National Law Journal.
5 minute read
May 31, 2007 |

King & Spalding Left Out of Longtime Client Coke's $4.1 Billion Deal

Industry observers have viewed Coca-Cola's purchase of Energy Brands and the Glaceau brand as Coke's embrace of the new world of vitamin-enhanced beverages. Coke may also be forging a new world among its transaction lawyers, as it tapped Skadden, Arps, Slate, Meagher & Flom instead of King & Spalding for the $4.1 billion cash deal. It's been called the biggest corporate acquisition in Coke's history, and the absence of King & Spalding is noticeable.
4 minute read
July 08, 2009 |

Justice Department Takes Stand Against 'Pay to Delay' Drug Deals

The practice is dubbed "pay to delay," or "reverse settlement." It happens when a brand-name drug company gives a generic challenger a lot of money, and the generic company agrees to keep its product off the market for a set number of years. These settlements are controversial but have been perfectly legal. Several federal appellate circuits have blessed the practice, and the DOJ under President Bush also supported it. But now, the Justice Department under President Obama is switching sides.
3 minute read

More from ALM

More from ALM

Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

Resources

  • Will Generative AIs Transform Legal Services? Defensibility and Security Must Be a Focus

    Brought to you by HaystackID

    Download Now

  • Unlocking the Power of Early Case Assessment Workflows

    Brought to you by Integreon

    Download Now

  • Good Legal Technology is Good Business: A Case for Bringing Employment Issues In-House

    Brought to you by LexisNexis®

    Download Now

  • Insights and Strategies for Effective Succession Planning in AM Law 100 Firms

    Brought to you by Gallagher

    Download Now

NEXT